A potent and selective inhibitor of the neuraminidase glycoprotein essential for replication of influenza A and B viruses.
Well tolerated orally active neuraminidase inhibitor.
Represents a useful therapeutic alternative to,
Zanamivir (especially in patients who prefer oral administration or who have an underlying respiratory disorder) and
The M2 inhibitors amantadine and rimantadine (because of their broader spectrum of anti-influenza activity and a lower likelihood of resistance) in patients with influenza.
Ideal treatment for immunocompromised patients, to prevent secondary complications.